Registry for patients undergoing TULSA procedure for prostate conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects data from patients who are undergoing or have undergone the transurethral ultrasound ablation (TULSA) procedure for prostate cancer and benign prostatic hyperplasia. The aim is to evaluate the real-world safety and efficacy of the TULSA procedure, as well as its impact on patients' quality of life over time. Patients will be followed up at regular intervals for several years, providing valuable insights into treatment outcomes and practice trends. The registry will help optimize patient care based on collected evidence.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Male
2. \>18 years old
3. Candidate for TULSA-PRO treatment
4. willing and able to sign the Informed Consent form

Exclusion Criteria:

None.

Where it's running

• RadNet's Liberty Pacific West Hills Facility
  West Hills, California, United States Recruiting
• Mayo Clinic Jacksonville
  Jacksonville, Florida, United States Recruiting
• Wellspan Health
  York, Pennsylvania, United States Recruiting
• University of Texas Southwestern Medical Center
  Dallas, Texas, United States Recruiting
• Urology Place
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: Gina Clarke
• Email: gclarke@profoundmedical.com
• Phone: 416-689-8156

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sonablate HIFU Registry for Prostate Cancer and BPH

  This registry collects real-world data from men treated with Sonablate HIFU to see how well it works and how it affects urinary and sexual function over the long term.

  Recruiting Sonablate · Indianapolis, Indiana · NCT07757490

• MRI-DTI look at the urethral sphincter ring and prostate base shape

  This imaging study tests how the male urethral internal sphincter ring appears on MRI-DTI and how it relates to prostate base morphology in men undergoing clinically indicated MRI.

  Recruiting Jiangsu Taizhou People's Hospital · Taizhou, Jiangsu · NCT07694752

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

• Bioblation: Combined biopsy and laser treatment for prostate symptoms and suspected cancer

  A single-session procedure (Bioblation) combines a trans-perineal prostate biopsy with laser ablation to relieve severe LUTS and treat likely low- to favorable intermediate-risk prostate cancer.

  Recruiting Benha University · Banhā, Qalyubia Governorate · NCT07526675

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.